Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Interferon beta-1a (ausschließlich zur subkutanen Anwendung), ATC L03AB07 f. d. Z. 01.11.26-31.10.28

Section 130a Paragraph 8 SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB. For the medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the above-mentioned active substance Interferon beta-1a (for subcutaneous use only), ATC L03AB07, the DAK-Gesundheit intends to conclude medicine discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine discount contracts. A discount contract pursuant to the licensing model for the above-mentioned active substance will enter into force for the first time on 01.11.2026 and will end on 31.10.2028. It will automatically end, regardless of this, with the entry into force of the exclusive contract.